ArticleCerebellum (London, England)2026
Non-paraneoplastic Autoimmune Cerebellar Ataxia with Sensory Ataxia Associated with the Anti-Ca/ARHGAP26 Antibody: A Case Report.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Primary (non-paraneoplastic) autoimmune cerebellar ataxia is immune-mediated and often responds to immunotherapy. The anti-Ca/ARHGAP26 antibody is a rare cause; reported experience comprises individual cases and small series, in which peripheral polyneuropathy but not central deep-sensory involvement is recognized. We report a man in his 50s with one month of subacute, progressive gait instability who had both cerebellar and deep-sensory ataxia. Proprioception and vibration sense were markedly impaired in the arms. Nerve conduction studies showed a steeply length-dependent axonal neuropathy: sural and superficial peroneal responses were markedly reduced, whereas ulnar responses were normal and median amplitudes mildly reduced. Arm proprioceptive loss was disproportionate to these findings, arguing against a sensory neuronopathy and suggesting involvement of the deep-sensory pathway proximal to the dorsal root ganglion. Spinal cord MRI was normal and whole-body PET/CT showed no evidence of malignancy. The antibody was negative in serum but positive at a low titer (1:10) in cerebrospinal fluid (CSF), supporting primary autoimmune cerebellar ataxia. Intravenous methylprednisolone with an oral taper produced marked, sustained recovery (modified Rankin Scale 3 to 1; Scale for the Assessment and Rating of ataxia 14 to 4), despite corticosteroid-induced hyperglycemia. To our knowledge this is the first anti-Ca/ARHGAP26 case in which cerebellar ataxia coexisted with a reversible deep-sensory deficit not attributable to the coexisting neuropathy. The case raises the hypothesis, not directly demonstrated here, that this antibody may target the central somatosensory pathway as well as the cerebellum. It also underlines the value of low-titer CSF antibody testing when serum is negative.
Indexed as
Identifiers
42814241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.